• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EIDOS:一种药物不良反应的机制分类。

EIDOS: a mechanistic classification of adverse drug effects.

机构信息

West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.

出版信息

Drug Saf. 2010 Jan 1;33(1):15-23. doi: 10.2165/11318910-000000000-00000.

DOI:10.2165/11318910-000000000-00000
PMID:20000863
Abstract

The mechanisms of adverse drug effects have not been adequately classified. Here, we propose a comprehensive mechanistic classification of adverse drug effects that considers five elements: the Extrinsic chemical species (E) that initiates the effect; the Intrinsic chemical species (I) that it affects; the Distribution (D) of these species in the body; the (physiological or pathological) Outcome (O); and the Sequela (S), which is the adverse effect. This classification, which we have called EIDOS, describes the mechanism by which an adverse effect occurs; it complements the DoTS classification of adverse effects (based on clinical pharmacology), which takes into account Dose responsiveness, Time course, and Susceptibility factors. Together, these two classification systems, mechanistic and clinical, comprehensively delineate all the important aspects of adverse drug reactions; they should contribute to areas such as drug development and regulation, pharmacovigilance, monitoring therapy, and the prevention, diagnosis, and treatment of adverse drug effects.

摘要

药物不良反应的机制尚未得到充分分类。在这里,我们提出了一种全面的药物不良反应机制分类,考虑了五个要素:引发效应的外源性化学物质 (E);它所影响的内源性化学物质 (I);这些物质在体内的分布 (D);(生理或病理)结果 (O);以及后遗症 (S),即不良反应。这种分类方法,我们称之为 EIDOS,描述了不良反应发生的机制;它补充了基于临床药理学的 DoTS 不良反应分类(基于剂量反应、时间过程和易感性因素)。这两种分类系统,即机制和临床分类,全面描述了药物不良反应的所有重要方面;它们应该有助于药物开发和监管、药物警戒、治疗监测以及预防、诊断和治疗药物不良反应等领域。

相似文献

1
EIDOS: a mechanistic classification of adverse drug effects.EIDOS:一种药物不良反应的机制分类。
Drug Saf. 2010 Jan 1;33(1):15-23. doi: 10.2165/11318910-000000000-00000.
2
Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.药物相关伤害的可预防程度 - 第二部分:基于分类药物不良反应的框架提出的标准。
Drug Saf. 2010 Nov 1;33(11):995-1002. doi: 10.2165/11538280-000000000-00000.
3
Pharmacoepidemiology and its input to pharmacovigilance.药物流行病学及其对药物警戒的贡献。
Therapie. 2016 Apr;71(2):211-6. doi: 10.1016/j.therap.2016.02.016. Epub 2016 Feb 6.
4
Modern methods of pharmacovigilance: detecting adverse effects of drugs.现代药物警戒方法:检测药物不良反应
Clin Med (Lond). 2009 Oct;9(5):486-9. doi: 10.7861/clinmedicine.9-5-486.
5
[From pharmacovigilance to pharmacoepidemiology and risk coordination].从药物警戒到药物流行病学与风险协调
Rev Med Interne. 2009 Dec;30 Suppl 4:S281-90. doi: 10.1016/j.revmed.2009.07.004. Epub 2009 Nov 4.
6
Pharmacovigilance in the pharmaceutical industry.制药行业中的药物警戒
Br J Clin Pharmacol. 1998 May;45(5):427-31. doi: 10.1046/j.1365-2125.1998.00713.x.
7
Monitoring and managing adverse drug reactions.
Am Pharm. 1992 Feb;NS32(2):74-81. doi: 10.1016/s0160-3450(15)31215-0.
8
[Pharmacovigiance: The spontaneous reporting system in Switzerland].[药物警戒:瑞士的自发报告系统]
Ther Umsch. 2015 Dec;72(11-12):743-8. doi: 10.1024/0040-5930/a000746.
9
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.用于评估药物不良反应的药物警戒:价值、组织与方法
Joint Bone Spine. 2006 Dec;73(6):629-32. doi: 10.1016/j.jbspin.2006.09.002. Epub 2006 Oct 12.
10
Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.欧洲和意大利的药物警戒工作流程及药物警戒术语。
Int J Clin Pharm. 2018 Aug;40(4):748-753. doi: 10.1007/s11096-018-0711-z. Epub 2018 Aug 9.

引用本文的文献

1
Insight into Risk Factors, Pharmacogenetics/Genomics, and Management of Adverse Drug Reactions in Elderly: A Narrative Review.老年人药物不良反应的风险因素、药物遗传学/基因组学及管理的深入探讨:一项叙述性综述
Pharmaceuticals (Basel). 2023 Nov 1;16(11):1542. doi: 10.3390/ph16111542.
2
Adverse drug reactions in older adults: a narrative review of the literature.老年人的药物不良反应:文献综述
Eur Geriatr Med. 2021 Jun;12(3):463-473. doi: 10.1007/s41999-021-00481-9. Epub 2021 Mar 18.
3
The use of mechanistic evidence in drug approval.

本文引用的文献

1
Medication errors: what they are, how they happen, and how to avoid them.用药差错:是什么、如何发生以及如何避免。
QJM. 2009 Aug;102(8):513-21. doi: 10.1093/qjmed/hcp052. Epub 2009 May 20.
2
A strategy for regulatory action when new adverse effects of a licensed product emerge.当已获许可产品出现新的不良反应时的监管行动策略。
Drug Saf. 2009;32(2):91-8. doi: 10.2165/00002018-200932020-00002.
3
Outbreak of adverse reactions associated with contaminated heparin.与受污染肝素相关的不良反应暴发。
在药物审批中使用机制性证据。
J Eval Clin Pract. 2018 Oct;24(5):1166-1176. doi: 10.1111/jep.12960. Epub 2018 Jun 11.
4
Causality Assessment in Pharmacovigilance: Still a Challenge.药物警戒中的因果关系评估:仍然是一项挑战。
Drug Saf. 2017 May;40(5):365-372. doi: 10.1007/s40264-017-0509-2.
5
Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.区分危害和伤害、药物不良效应和药物不良反应:对药物开发、临床试验、药物警戒、生物标志物和监测的影响。
Drug Saf. 2013 Mar;36(3):147-53. doi: 10.1007/s40264-013-0019-9.
6
Pharmacovigilance.药物警戒
Br J Clin Pharmacol. 2012 Jun;73(6):979-82. doi: 10.1111/j.1365-2125.2012.04249.x.
7
Adverse drug reactions.药物不良反应
Br J Clin Pharmacol. 2012 Jun;73(6):908-11. doi: 10.1111/j.1365-2125.2012.04235.x.
8
Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.药物相关伤害的可预防程度 - 第二部分:基于分类药物不良反应的框架提出的标准。
Drug Saf. 2010 Nov 1;33(11):995-1002. doi: 10.2165/11538280-000000000-00000.
9
A manifesto for clinical pharmacology from principles to practice.从原则到实践:临床药理学宣言。
Br J Clin Pharmacol. 2010 Jul;70(1):3-13. doi: 10.1111/j.1365-2125.2010.03699.x.
10
Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff.药物相互作用与药物不良反应:分清主次
Wien Klin Wochenschr. 2010 Feb;122(3-4):62-4. doi: 10.1007/s00508-010-1309-1.
N Engl J Med. 2008 Dec 18;359(25):2674-84. doi: 10.1056/NEJMoa0806450. Epub 2008 Dec 3.
4
Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model.肼在肝细胞炎症模型中异烟肼诱导的肝毒性中的作用。
Toxicol Appl Pharmacol. 2008 May 15;229(1):94-101. doi: 10.1016/j.taap.2008.01.002. Epub 2008 Jan 17.
5
Antenatal exposure to DES: lessons learned...future concerns.
Obstet Gynecol Surv. 2007 Aug;62(8):548-55. doi: 10.1097/01.ogx.0000271138.31234.d7.
6
The effect of the choice of irrigation fluid on cardiac stress during transurethral resection of the prostate: a comparison between 1.5% glycine and 5% glucose.经尿道前列腺切除术期间冲洗液的选择对心脏应激的影响:1.5% 甘氨酸与 5% 葡萄糖的比较
J Urol. 2007 Apr;177(4):1369-73. doi: 10.1016/j.juro.2006.11.042.
7
Anecdotes that provide definitive evidence.提供确凿证据的轶事。
BMJ. 2006 Dec 16;333(7581):1267-9. doi: 10.1136/bmj.39036.666389.94.
8
Adverse side-effects to biological agents.生物制剂的不良副作用。
Allergy. 2006 Aug;61(8):912-20. doi: 10.1111/j.1398-9995.2006.01058.x.
9
Toxicophores: investigations in drug safety.毒效基团:药物安全性研究
Toxicology. 2006 Sep 1;226(1):1-11. doi: 10.1016/j.tox.2006.05.101. Epub 2006 Jun 9.
10
Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.
Drug Saf. 2006;29(7):557-66. doi: 10.2165/00002018-200629070-00002.